Abacavir+Lamivudine bulk supplier for pharma manufacturers

Abacavir+Lamivudine 600mg+300mg Suppliers & Bulk Manufacturers

Available Forms: Tablets / Oral solution

Available Strengths: 600mg+300mg

Reference Brands: Epzicom (USA), Kivexa(USA/EU), Ziagen (USA/EU)

Abacavir/Lamivudine is a fixed-dose antiretroviral combination used in the treatment of HIV-1 infection. It combines two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the reverse transcriptase enzyme, preventing viral replication and reducing viral load in patients.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Abacavir+Lamivudine — third party manufacturing & bulk supply

Abacavir+Lamivudine 600mg+300mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Abacavir+Lamivudine is supplied as Tablets / Oral solution — supplied in more than one dosage form, each with its own manufacturing economics, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Abacavir+Lamivudine listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Abacavir+Lamivudine →

Back to Listing

Frequently Asked Questions

Abacavir and Lamivudine are used together as part of combination antiretroviral therapy for the treatment of HIV-1 infection. This fixed-dose combination helps lower viral load, improve immune function, and reduce the progression of HIV when used with other antiretroviral medicines.

This combination contains two active ingredients: abacavir, a nucleoside reverse transcriptase inhibitor (NRTI) that blocks viral DNA chain elongation, and lamivudine, another NRTI that interferes with viral replication by inhibiting reverse transcriptase. Together, they provide dual NRTI backbone coverage.

The most recognized international trade names for this combination are Kivexa and Epzicom. Several generic brands also exist in different markets.

Kivexa and Epzicom are manufactured by ViiV Healthcare, a joint venture of GSK, Pfizer, and Shionogi.

The generic name of the product is abacavir and lamivudine.

Common brand names include Kivexa and Epzicom, along with various generic versions depending on the region.

Abacavir and Lamivudine combination products (Kivexa/Epzicom) are manufactured by ViiV Healthcare in its approved global facilities. Generic formulations are widely produced in India and other countries by licensed pharmaceutical manufacturers based on regulatory approvals.